Gegen Rezeptorprotein Gerichtetes Therapeutikum, Testmittel, an Rezeptorprotein Bindender Antikörper und Screeningverfahren für Molekular Gerichtete Arzneimittel
EP4748394
27. Mai 2026
Anmelder: National University Corporation Tokai National Higher Education and Research System 🇯🇵
Details
- Veröffentlichungs-Nr.
- EP4748394
- Anmeldetag
- 25. Januar 2019
- Veröffentlichung
- 27. Mai 2026
- Rechtsraum
- EP
Abstract
From gene expression analysis with a long-term recurrence-free group and a recurrence metastasis group of stomach cancer, CHRNB2 and NPTXR were identified as drug discovery targets. Tumor growth was successfully inhibited by an antibody medicine or a nucleic acid medicine targeting CHRNB2 or NPTXR. Furthermore, a polyclonal antibody and a monoclonal antibody linking to CHRNB2 or NPTXR are provided. Since these receptor molecules are novel molecular targets, treatment of cases which the existing therapeutic drugs have no effect on is made possible.
Anmelder
- Firma
- National University Corporation Tokai National Higher Education and Research System
- Land
- 🇯🇵 Japan